0000950170-24-018175.txt : 20240221 0000950170-24-018175.hdr.sgml : 20240221 20240221174522 ACCESSION NUMBER: 0000950170-24-018175 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240218 FILED AS OF DATE: 20240221 DATE AS OF CHANGE: 20240221 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KASINGER JAMES R. CENTRAL INDEX KEY: 0001708172 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37923 FILM NUMBER: 24661317 MAIL ADDRESS: STREET 1: C/O CRISPR THERAPEUTICS, INC. STREET 2: 610 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CRISPR Therapeutics AG CENTRAL INDEX KEY: 0001674416 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 473173478 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 BUSINESS PHONE: 6173154600 MAIL ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 4 1 ownership.xml 4 X0508 4 2024-02-18 0001674416 CRISPR Therapeutics AG CRSP 0001708172 KASINGER JAMES R. C/O CRISPR THERAPEUTICS 105 WEST FIRST STREET BOSTON MA 02127 false true false false General Counsel and Secretary false Common Shares 2024-02-18 4 M false 3825 A 59284 D Common Shares 2024-02-20 4 S false 1913 79.67 D 57371 D Restricted Stock Units 2024-02-18 4 M false 3825 D Common Shares 3825 7650 D Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Includes 615 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026. /s/ AJ Silver, attorney-in-fact 2024-02-21